Supplementary Figure S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors

Ian M. Silverman; Joseph D. Schonhoft; Benjamin Herzberg; Arielle Yablonovitch; Errin Lagow; Patrick Fiaux; Pegah Safabakhsh; Sunantha Sethuraman; Danielle Ulanet; Julia Yang; Insil Kim; Paul Basciano; Michael Cecchini; Elizabeth K. Lee; Stéphanie Lheureux; Elisa Fontana; Benedito A. Carneiro; Jorge S. Reis‐Filho; Timothy A. Yap; Michael Zinda; Ezra Y. Rosen; Victoria Rimkunas

doi:10.1158/1078-0432.30255602

Key Points

The analysis reveals a significant correlation between ctDNA profiling and clinical disease burden, highlighting potential diagnostic value.
Clinical measures show a strong relationship with epigenomic and genomic changes in patients, suggesting relevant prognostic insights.
This observational analysis emphasizes the role of ctDNA in detecting disease burden in tumors, which may guide future therapies.
Further research is essential to validate these findings in broader populations with various tumor types.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Analysis shows a link between genomic measures and clinical disease burden in patients with tumors, indicating potential implications for treatment paths.

Abstract

Relationship between TF measures and clinical disease burden.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Silverman et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a7f https://doi.org/10.1158/1078-0432.30255602

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading